Cannabis improved Crohn disease symptoms in small trials but did not reduce inflammation markers

Among the three existing placebo-controlled trials in active Crohn disease (93 subjects total), two showed significant clinical improvement (reduced CDAI scores) but no improvement in inflammatory markers. About 15% of IBD patients use cannabis to manage symptoms. The complexity of cannabis chemovars and the diversity of cannabinoid compounds create inherent research challenges.

Expert review of clinical evidence on cannabis for Crohn disease, focusing on three placebo-controlled trials and the broader landscape of cannabinoid research in IBD.

Cannabis use is common among IBD patients, but the disconnect between symptom improvement and unchanged inflammation markers raises important questions about whether cannabis masks symptoms rather than treating the underlying disease.

If cannabis improves how patients feel but does not address the underlying inflammation driving Crohn disease, patients might feel better while their disease silently progresses. This makes understanding the mechanism of benefit critical.

Only 3 small RCTs available; 93 total subjects is very limited; cannabis products and doses varied; short trial durations; inflammatory markers may not capture all types of immune activity.